News & Updates

A novel once-a-day inhaler for asthma that contains a fixed-dose combination of the corticosteroid mometasone furoate (MF), the long-acting beta-agonist indacaterol acetate (IND), and the long-acting muscarinic antagonist glycopyrronium bromide (GLY) appears to have a favourable effect in patients with persistent airflow limitation (PAL), according to a post hoc analysis of the IRIDIUM study.

The phase III STELLAR trial lives up to its name, delivering stellar results and offering hope for patients with pulmonary arterial hypertension (PAH), a rare, progressive, life-threatening disorder affecting the heart and lungs, by adding sotatercept – a novel first-in-class activin signalling inhibitor – to background therapy.

Prenatal exposure to plastic-derived chemicals, such as bisphenol A (BPA) and phthalates, tends to increase the risk of asthma, particularly in males, a study has shown.

Early treatment with a single dose of pegylated recombinant IL-29 type III interferon (IFN), otherwise known as peg lambda, significantly reduced clinical events in the phase III TOGETHER study evaluating mostly vaccinated, acutely symptomatic COVID-19 outpatients.

Patients with idiopathic pulmonary fibrosis (IPF) who have high exposure to nitrogen dioxide (NO2) are at greater risk of disease progression, suggests a recent study.

Breathing exercise devices such as a conventional threshold loading training (TLT) device or an innovative respiratory training (IRT) device, when used in combination with lower torso sports training (LTST), proved beneficial in improving pulmonary function, exercise capacity, and quality of life (QoL) in individuals with asthma, a study suggests. However, IRT trumped TLT in terms of improvements in some respiratory and physical performance variables.